Article
12 Sep 2025
DTC Reforms And MAHA Proclamations: The MAHA Agenda And Its Focus On Prescription Drugs Continues To Take Shape
AUTHORS CONTENT
Article
22 Apr 2025
Trump Administration Issues Executive Order To Lower Prescription Drug Costs
Article
09 Oct 2024
September 2024 Medicaid Rebate Final Rule: Key Issues For Manufacturers
Article
11 Jul 2024
When APA Claims Accrue Under Corner Post: Implications For The Life Sciences Industry
Article
03 Jul 2024
Chevron Overturned: What Does It Mean For Life Sciences Companies?
Article
27 Oct 2023
FDA Updates Off-Label Communications Guidance
Article
22 Jul 2022
OIG Advisory Opinion On Continuing Education Provides Insight On Risk Areas
Article
02 May 2022
Arnold & Porter Life Sciences: Pharmaceutical Pricing & Contracting (Video)
Article
26 Jan 2022
HHS-OIG Rule Expands Opportunities For Advisory Opinions
Article
25 Nov 2021
Biden Administration Issues Rules Requiring Insurer Transparency On Drug Spending, Rebates And Fees: What Manufacturers Need To Know
Article
25 Nov 2020
Pharmacy Point-Of-Sale Price Concession And PBM Service Fee Safe Harbor Final Rule May Reshape Medicare Part D: What Pharmaceutical Manufacturers Need To Know Now
Article
01 Oct 2020
FDA Issues Proposed Rule To Amend Intended Use Regulations
Article
27 Jan 2020
A New Private Right Of Action Is Created For Refusals To Provide Drugs And Biologics To Certain Product Developers
Article
02 Jan 2020
Questions & Answers Guide To FDA's Prescription Drug Importation Proposals
Article
29 Oct 2019
HHS Proposes New Protections For Value-Based Arrangements And Other Revisions To AKS Safe Harbors, CMP Exceptions And Stark Exceptions
Article
05 Aug 2019
The Trump Administration Drug Importation Action Plan
Article
11 Feb 2019
HHS OIG's Proposed Rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals
Article
15 Jan 2019
Is DOJ Feeling Charitable? DOJ Files Statement Of Interest Regarding Manufacturer Donations To Charity Patient Assistance Programs
Article
18 Jun 2018
FDA Finalizes Guidance Documents On Payor Communications And Communications Consistent With Labeling
Article
16 May 2018
Trump Administration Issues Blueprint To Lower Drug Prices And Reduce Out-Of-Pocket Costs